Latest News From Lumira Ventures

Satsuma Pharmaceuticals Raises $62 Million in Series B Preferred Stock Financing

Jennifer Schram Main Page, Portfolio News, Press Release, Satsuma Pharmaceuticals

Funding supports Phase 3 development of STS101 for the acute treatment of migraine, including pivotal Phase 3 efficacy trial with planned initiation in Q3 2019 SOUTH SAN FRANCISCO, Calif., April 24, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a clinical-stage biopharmaceutical …

Bardy Diagnostics™ Announces $35.5M in Series B Funding Round

Jennifer Schram BardyDx, Main Page, Portfolio News, Press Release

SEATTLE, April 16, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it has raised $35.5 million in Series B funding, led by River Cities Capital Funds with participation from new investors HealthQuest Capital, Aperture Venture Partners, Aphelion …

Aurinia Pharmaceuticals Inc. Announces New CEO and Board Director and Appoints New Chairman of the Board

Jennifer Schram Aurinia Pharmaceuticals, Portfolio News, Press Release

SOURCE: Aurinia Pharmaceuticals Inc. VICTORIA, British Columbia–(BUSINESS WIRE) — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr. Peter Greenleaf …

Opsens Q2 2019 Revenues Reach a Record Level

Jennifer Schram Opsens, Portfolio News, Press Release

QUEBEC CITY, April 11, 2019 /CNW Telbec/ – Opsens Inc. (“Opsens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF) today reported its results for the second quarter of 2019. HIGHLIGHTS Consolidated revenues totaled $7.9M in the second quarter of 2019 compared with $5.4M in the corresponding period in 2018, an increase of $2.5M or …